Supernus and Indivior complete merger, creating $2.2bn CNS pharma group

Supernus, Inc. (NASDAQ: SUPN) has formally completed the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., creating a larger biopharmaceutical company focused on central nervous system disorders. The transaction closed on November 2, 2026, combining an 11-product commercial portfolio with approximately $2.2 billion in historical pro forma annual revenue and expected annual cost synergies of $125 million. Former Indivior shareholders own approximately 56.5% of the combined company, while former Supernus Pharmaceuticals shareholders own the remaining 43.5% on a fully diluted basis. The merger also involves a $1 billion special cash dividend for former Indivior shareholders, partly financed through new borrowing, making future cash generation and the integration of commercially distinct medicine portfolios central to the investment case.

How does the completed Supernus and Indivior merger change ownership and control?

The transaction has been structured as an all-stock merger of equals, with legacy Supernus Pharmaceuticals shareholders receiving 1.5401 shares of Indivior Pharmaceuticals for each Supernus share held. Following completion, Indivior Pharmaceuticals was renamed Supernus, Inc., becoming the publicly traded parent of the combined business. Legacy Supernus Pharmaceuticals became a wholly owned subsidiary of that renamed company.

This legal structure is particularly relevant because the public company now trading under SUPN is not the same listed legal entity that used the symbol before the merger. The original Supernus Pharmaceuticals listing was discontinued, while the former Indivior public company adopted the Supernus name and ticker. Investors comparing historical share prices must account for that change in security identity.

The merged business is headquartered in Rockville, Maryland, with Jack Khattar, formerly chief executive officer of Supernus Pharmaceuticals, serving as president and chief executive officer. Tony Kingsley, previously a director of Indivior, has become chairman of the eight-member board. Governance is evenly divided between the two legacy organisations, with four directors appointed from each.

The ownership split nevertheless gives former Indivior investors the larger economic stake. Their approximately 56.5% interest reflects the agreed transaction structure, while legacy Supernus investors participate through the 43.5% ownership allocation. The difference between equal board representation and unequal economic ownership is an important feature of the completed merger.

Why are Supernus and Indivior combining neurological and addiction medicines?

The combined company operates across opioid use disorder, psychiatry, neurology and related central nervous system conditions. Its five identified core growth products are SUBLOCADE, Qelbree, GOCOVRI, ONAPGO and ZURZUVAE. These medicines address different patient populations and treatment settings, providing greater product diversification than either company possessed independently.

Indivior brings an established opioid use disorder business led by SUBLOCADE, an extended-release buprenorphine injection used in treating opioid dependence. Its commercial platform includes specialised treatment relationships and experience within addiction medicine. Supernus contributes products addressing attention-deficit hyperactivity disorder, Parkinson’s disease and other neurological or psychiatric conditions.

The acquisition rationale rests partly on combining commercial operations with different therapeutic strengths. A broader portfolio can provide additional opportunities to deploy sales, medical affairs, regulatory and administrative capabilities across several medicines. However, the clinical specialists, prescribing pathways and patient support requirements vary considerably between addiction treatment and neurological disorders.

The integration therefore requires more than combining product catalogues. Management must preserve the specialised commercial relationships associated with each medicine while identifying genuinely overlapping costs. Excessive consolidation could weaken therapeutic expertise if distinct products are managed through an overly uniform operating structure.

The expanded portfolio also offers greater resilience against dependence on any single drug. Nevertheless, concentration has not disappeared because SUBLOCADE remains a particularly important revenue contributor. The strength of that franchise will influence the combined group’s profitability and ability to finance pipeline development.

What do Indivior’s record third-quarter results reveal about the merger?

Indivior reported third-quarter 2026 net revenue of $356 million, an increase of 13% from the corresponding period of 2025. SUBLOCADE revenue rose 22% to a record $267 million, supported by growth in prescription volumes and favourable commercial factors. The medicine represented approximately 75% of Indivior’s total quarterly revenue, demonstrating its central position in the legacy business.

The company also generated record quarterly adjusted EBITDA of $211 million, compared with $120 million a year earlier. Its adjusted EBITDA margin increased to approximately 59%, reflecting a combination of higher revenue and reduced operating expenses. Reported net income reached $137 million.

These figures provide an attractive earnings base for the combined company, but they also highlight the importance of sustaining SUBLOCADE’s performance. The treatment’s revenue growth contributed substantially to operating leverage, meaning changes in prescription demand, reimbursement or competitive conditions could have significant financial consequences.

Indivior reported approximately $332 million in cash and investments at September 30, 2026. This balance provides a historical reference for its contribution to the merger, although the subsequent dividend financing and transaction-related cash movements change the relevant post-closing position.

The latest results indicate that Indivior entered the combination with improving profitability rather than depending on the merger to reverse an immediate operating decline. Whether those margins can be maintained during integration will be an important measure of execution quality.

How strong was Supernus Pharmaceuticals before the combination?

Legacy Supernus Pharmaceuticals reported third-quarter revenue of $226.8 million, an increase of approximately 18% year on year. Revenue from its four identified growth products reached $192.2 million, representing growth of 29%. These products accounted for approximately 85% of the company’s quarterly revenue, illustrating the increasing contribution of its newer commercial portfolio.

Qelbree generated $90.8 million in quarterly net sales, up 12%, while GOCOVRI revenue increased approximately 4% to $42.6 million. ONAPGO revenue reached $17.1 million, reflecting substantial growth from its earlier commercial base. Supernus also reported $41.7 million in ZURZUVAE collaboration revenue, representing its contractual share of net revenues recorded by Biogen.

The ZURZUVAE arrangement is financially different from a product that Supernus markets and books entirely through direct sales. Its collaboration revenue reflects an agreement with Biogen rather than the full gross sales generated by the medicine. The revenue recognition distinction must be preserved when comparing the economics of individual products.

Supernus reported quarterly net earnings of $20.9 million, compared with a loss of $45.1 million in the year-earlier period. Cash, cash equivalents and current marketable securities reached approximately $359.5 million at September 30.

The company’s product growth provides a complementary earnings opportunity alongside Indivior’s addiction medicines. However, the products operate at different stages of commercial maturity, and their contribution to future profitability will depend on continued prescription growth, market access and investment.

How does the $1 billion special dividend affect Supernus’ balance sheet?

The merger includes a one-time special cash dividend of approximately $1 billion for qualifying former Indivior shareholders. The declared distribution amounts to $8.13 per eligible share, with payment scheduled for November 6, 2026. It is associated with the completed transaction rather than an indication that the merged company has adopted a recurring dividend policy.

The companies financed the distribution using a $650 million term loan commitment provided by Citibank, N.A., with the remaining amount funded from existing cash. The arrangement transfers a substantial portion of value to legacy Indivior shareholders while introducing additional borrowing obligations into the combined company.

This financing structure changes how investors should assess the merger’s financial benefits. While the combined business gains a larger commercial portfolio and stronger operating scale, a portion of its future cash generation will be required to service debt and support the enlarged organisation’s capital needs.

Before completion, the companies presented illustrative pro forma net debt of approximately $878 million, based on June 30 financial information and assumptions including the new borrowing and special dividend. That calculation did not incorporate every transaction cost, financing fee or cost required to achieve the anticipated synergies.

The actual post-closing balance sheet will therefore be more informative than the original illustration. Investors need to understand the final cash position, outstanding debt, interest expense and integration obligations before concluding that the merged business has materially increased its financial flexibility.

Can the combined company realise $125 million in annual cost synergies?

Management expects at least $125 million in annual cost synergies from the combination, with the original merger presentation indicating that these savings could be achieved within approximately 12 months after completion. The projected benefits primarily involve overlapping general and administrative functions and operational efficiencies. They do not represent additional revenue or guaranteed improvements in product demand.

The companies previously presented pro forma adjusted EBITDA of approximately $888 million for the 12 months ended June 30, 2026, including the anticipated $125 million synergy contribution. That figure is therefore not simply historical earnings generated by the two businesses before combination. It incorporates benefits that management expects to realise in the future.

Excluding the identified synergies, the same illustrative framework implies approximately $763 million in underlying combined adjusted EBITDA. The difference provides perspective on how much of management’s pro forma profitability assumption depends on successfully implementing the cost reduction programme.

The projected savings represent approximately 5.7% of the previously disclosed $2.2 billion annual revenue base. This suggests that substantial operating benefits could potentially be achieved without requiring transformational changes to the underlying product portfolios. However, the costs of restructuring and integrating operations must also be considered.

Management will need to demonstrate that administrative savings do not weaken essential medical, regulatory or commercial capabilities. Pharmaceutical businesses must continue meeting stringent requirements involving product quality, pharmacovigilance, manufacturing and scientific support, making indiscriminate cost reductions commercially and operationally undesirable.

The next quarterly and annual reporting periods will provide opportunities to compare realised savings with the original synergy target. Separate disclosure of integration costs and recurring expense reductions would help distinguish genuine improvements from temporary changes in reported profitability.

Why does Supernus stock appear to have fallen 33% after the merger?

Some market-data services show the SUPN ticker declining by approximately 32.9% on November 3, from the legacy Supernus Pharmaceuticals closing price of $41.92 on October 30 to approximately $28.15. However, that apparent movement is complicated by the merger and the reuse of the ticker symbol.

The original Supernus Pharmaceuticals shares ceased trading independently after the merger. The company now using the SUPN symbol is the former Indivior Pharmaceuticals public entity, which changed its name following completion. The new security therefore has a different corporate and ownership history from the previous company using the ticker.

The special $8.13-per-share Indivior dividend also changed the economic position of qualifying shareholders. A cash distribution of that scale affects comparisons between pre-dividend and post-dividend stock valuations, particularly when the same corporate action coincides with a change in trading symbol.

Comparing the legacy SUPN price directly with the new SUPN price can consequently produce a misleading impression of shareholder losses. A proper return calculation would need to follow the relevant shareholder’s original securities, the 1.5401 exchange ratio where applicable and any cash dividend entitlement.

The new Supernus shares closed at approximately $28.21 on November 4, compared with $28.15 in the preceding session, representing a modest increase of around 0.2%. The stock’s equity market capitalisation was approximately $5.9 billion based on the new share count and closing quotation.

Investor sentiment should therefore be evaluated using the combined company’s new trading history rather than treating the raw ticker discontinuity as evidence of a sudden collapse in market confidence.

What role will pipeline development play in the combined company’s growth?

Supernus enters the merger with several clinical development programmes that could broaden its commercial portfolio over time. These include SPN-817, under investigation for treatment-resistant focal seizures, and SPN-820, being studied for major depressive disorder. Both programmes were in Phase 2b development at the time of the latest legacy Supernus update.

The company has also outlined plans to advance SPN-443, an investigational stimulant for attention-deficit hyperactivity disorder, into early clinical development. These programmes offer potential future products but remain subject to clinical evidence, regulatory requirements and additional investment. They should not be treated as approved therapies or assured future revenue contributors.

The combined company’s stronger commercial earnings base could provide additional capacity to support development. However, the cash requirements associated with the special dividend financing and integration programme will influence how much financial flexibility is available for research and development.

Management will need to prioritise programmes based on their clinical progress, commercial potential and development costs. Maintaining a balanced pipeline is especially relevant because the combined business depends on a relatively small group of core growth medicines despite operating an 11-product portfolio.

The most important evidence will involve progress against specified clinical endpoints, regulatory submissions and commercially justified investment decisions. Pipeline breadth by itself does not establish future value unless development programmes produce successful clinical and regulatory outcomes.

What financial evidence will validate the completed Supernus and Indivior merger?

The combination has created a larger company with established medicines in addiction treatment, psychiatry and neurology. Both legacy businesses entered the transaction with growing quarterly revenue, while Indivior contributed a substantial earnings base through SUBLOCADE. The completed structure also provides management with a broader platform for commercial expansion and potential future acquisitions.

However, historical revenue and EBITDA figures must now be distinguished from the financial performance of the newly combined organisation. Both companies withdrew the applicability of their standalone guidance following completion, making a new consolidated outlook an important requirement for investors.

The $125 million synergy target offers a specific measure of integration success. The $650 million term loan associated with the special dividend creates another measurable obligation, making operating cash generation and debt reduction relevant alongside product sales growth.

A sustained improvement in combined cash flow, particularly after integration spending and interest costs, would strengthen the financial case for the merger. Conversely, weaker growth in the core medicines or delays in achieving savings could reduce the expected benefits.

Supernus has completed the legal combination, bringing an end to the transaction approval process and beginning the more demanding operational phase. The next decisive proof point will be management’s first comprehensive consolidated financial disclosures, including updated guidance, the final post-merger balance sheet and progress towards the $125 million annual cost savings target.

What should investors know about the completed Supernus and Indivior merger?

• Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026.
• The combined public company is Supernus, Inc., trading under the Nasdaq ticker SUPN from November 3.
• Former Indivior shareholders own approximately 56.5%, with legacy Supernus shareholders holding 43.5%.
• Legacy Supernus shareholders received 1.5401 Indivior shares for each former Supernus share.
• The combined company has 11 commercial medicines, including five identified core growth products.
• Management has identified approximately $2.2 billion in historical pro forma annual revenue.
• The merger includes a $1 billion special dividend for qualifying legacy Indivior shareholders, partly financed through a $650 million term loan.
• Management expects at least $125 million in annual cost synergies.
• The apparent 33% decline in historical SUPN ticker data reflects a complex merger-related change in security identity and dividend treatment, not a directly comparable single-stock return.
• Updated consolidated guidance, realised synergies and post-merger cash generation will provide the most useful evidence of financial performance.